BTAI
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- BioXcel Therapeutics entered into an agreement to sell assets to Teva PharmaceuticalsAug 28, 2026
- BioXcel enrolled first patients in a U.S. government-funded study of BXCL501 for acute stressApr 8, 2026
- BioXcel received FDA acceptance of sNDA for IGALMI for at-home useApr 1, 2026
- BioXcel Therapeutics reported positive Phase 2 topline results from a Columbia University-led study of BXCL501 for opioid withdrawal treatmentMar 5, 2026
- BioXcel Therapeutics submitted sNDA for IGALMI at-home use expansionJan 20, 2026